One year treatment with lisuride delivery pump in Parkinson's disease.
1. A group of 14 fluctuating Parkinsonian patients underwent the subcutaneous Lisuride treatment, administered by an insulin delivery pump. Clinical response has been studied during a one year period. 2. Some patients (8 out of 14) were in combined therapy, assuming a relative small amount of oral L-Dopa together with subcutaneous Lisuride. 3. Lisuride confirmed, also by the subcutaneous route, its antiparkinsonian properties, without any loss of therapeutical efficacy during the 12 month period considered. 4. 7 patients dropped-out from the study, due to psychiatric or systemic side-effects and to "technical" management of the pump. 5. The only 2 patients assuming a 24 hour regimen of Lisuride infusion were among the withdrawn subjects. They were also the only to complain severe psychiatric disturbances.
Ruggieri
S
S
Department of Neurological Sciences, University La Sapienza, Rome, Italy.
Stocchi
F
F
Carta
A
A
Bragoni
M
M
Agostini
C
C
Barbato
L
L
Agnoli
A
A
D000328:Adult; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007980:Levodopa / Q000627:therapeutic use; D008090:Lisuride / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D004873:Ergolines; D007980:Levodopa; D008090:Lisuride